Although rare, antibodies against the receptor-binding domain of SARS-CoV-2 that showed potent antiviral activity were obtained from all tested convalescent individuals, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
- Davide F. Robbiani
- Christian Gaebler
- Michel C. Nussenzweig